濮阳东方医院治疗早泄技术可靠濮阳东方男科医院好吗,濮阳东方妇科评价如何,濮阳东方医院口碑好服务好,濮阳东方看男科病怎么样,濮阳东方医院治疗阳痿正规吗,濮阳东方医院男科治阳痿方法,濮阳东方医院男科怎么样

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

SUVA, Sept. 21 (Xinhua) -- The Secretariat of the Pacific Community (SPC) stressed on Wednesday that sustainable use and management of forests and tree resources will remain its important focus for the foreseeable future.Sairusi Bulai, a forestry team coordinator of SPC's Land Resources Division (LRD) told a regional workshop currently underway in Fiji's western tourist city of Nadi that "our main issue was and continues to be the lack of adequate resources to enable countries to effectively implement sustainable forest management.""Therefore, we are very fortunate that we have this opportunity to discuss findings and recommendations of the mission, which the UN-REDD Program has undertaken in the Pacific earlier this year," he added.REDD+ is a new international mechanism to compensate developing countries for reducing their rate of deforestation and forest degradation and increasing their carbon stocks.Developing countries participate on a voluntary basis. They provide technical and financial assistance to enable eligible countries to meet the requirements for future participation. Once a country begins participating, it receives compensation for its verified reduction in carbon emission from forest activities.The UN-REDD Program is a collaborative partnership of the United Nations Development Program (UNDP), the United Nations Environment Program (UNEP) and the Food and Agriculture Organization (FAO) to support countries in the preparation of this mechanism.Bulai encouraged participants to take advantage of the excellent opportunity to discuss REDD+ experiences in the region and to link up with the experts in attendance.REDD+ gives an excellent opportunity to create better awareness and understanding amongst all stakeholders, including resource owners, so that informed decisions are made to avoid exploitation, he said.Bulai, meanwhile, stressed on the critical importance of multi- sectoral as well as multi-stakeholder based approaches to forest management to effectively reduce deforestation and forest degradation.

CHENGDU, Sept. 20 (Xinhua) -- A United Nations official said Tuesday that she hopes China will take every opportunity to reinforce, support and lead the UN's agenda and "infuse it with strength and wisdom.""The more China gives, the better the UN can become," said Renata Lok-Dessallien, UN Resident Coordinator and United Nations Development Program (UNDP) Resident Representative in China, at the Seminar in Memory of the 40th Anniversary of the Resumption of Lawful Rights of China in the United Nations.The three-day seminar from Sept. 19 to 21 is being held in the city of Chengdu in southwest China's Sichuan Province. About 100 UN and Chinese officials are gathering to discuss China's role in the UN, as well as the UN's role in global diplomacy.Lok-Dessallien said that the General Assembly Resolution of Oct. 25, 1971 was an "important milestone in China's international relations and in the history of the United Nations.""It restored the rights of the People's Republic of China in the United Nations and marked China's entry to the world stage," she said.Steven Sabey, a senior policy advisor from the UNDP's China office, said that China plays an important role in facilitating cooperation about the member states of the United Nations."China needs the United Nations, and the United Nations also needs China," said Wu Hailong, China's assistant minister of foreign affairs."We must recognize that as the largest developing country in the world, China needs to manage its domestic affairs first, as this can have a positive effect on humanity as a whole," Wu said.As China's role in the world continues to grow and evolve, the UN's role in China will also grow, according to Lok-Dessallien."As China's development trajectory continues to evolve, we are entering significantly new territory in the UN-China relationship," she said.Sabey said that he hopes China will strengthen its cooperation with the United Nations in order to further improve intercultural communication and allow China to contribute more to other developing countries."The United Nations is committed to continuing to deepen and strengthen our partnership as we tackle the many global challenges ahead," said Lok-Dessallien.

LOS ANGELES, June 20 (Xinhua) -- About 8 percent of children, or nearly 6 million in the U.S., have a food allergy, a much higher rate than previously estimated, a new study suggests.Not only is this estimate higher than some previous research has reported, allergic reactions are often severe and that many kids have more than one allergy, according to the study published online in Pediatrics on Monday.Of the children with confirmed (or probable) food allergies, about 39 percent had had severe reactions in the past, and 30 percent had more than one allergy, the study found.In the current study, researchers at the Northwestern University Feinberg School of Medicine surveyed parents of more than 38,000 children about whether their child had been diagnosed with a food allergy and had one or more of a number of symptoms, including anaphylaxis; swelling of the lips, eyes or face and skin rashes or hives.The study pinned down peanuts (25 percent of food-allergic children), milk (21 percent) and shellfish (17 percent) as the top three allergens.Severe reactions were most common among children with tree nut (more than 50 percent) and fin fish (more than 40 percent) allergies. The reactions were more likely among 14- to 17-year- olds compared with 0- to 2-year-olds, and more likely in children with multiple food allergies, the study found."These findings provide critical epidemiologic information to guide strategies for the prevention of food-induced reactions and for the diagnosis and management of childhood food allergies," the study noted.

BEIJING, Sept. 4 (Xinhua) -- China's railway system has transported some 1.27 billion passengers during the first eight months of this year, up 11.8 percent from a year earlier, the Ministry of Railways said Sunday.The figure has accounted for 67.4 percent of the ministry's full-year target, said the ministry in a statement on its website.The Ministry of Railways has planned to send 1.9 billion passengers in 2011, up 13.1 percent year-on-year.The country's high-speed trains had been operating with improved order and efficiency, said the ministry, which has been required to run high-speed trains at slower speeds, as well as to reorganize bullet train schedules nationwide, for safety reasons.The State Council, or Cabinet, ordered increased safety checks after a fatal train collision that killed 40 people in July raised concerns over the safety of the country's high-speed railways.The ministry cut the number of high-speed trains running between Beijing and Shanghai to 66 pairs from 88 pairs per day, effective as of Aug. 16.Meanwhile, the railways transported more than 2.6 billion metric tons of goods from January to August, up 7.8 percent year-on-year, the ministry said.